Preparing For The Return Of Public Markets

Biotech investment is in abeyance after an unprecedented twelve-year run, according to Gregg Beloff, managing director of Danforth Advisors. The capital markets will be back and industry must continue to operate while the bear market persists.

Panelists at LSX World Congress 2023
L-R: Gregg Beloff, Houman Ashrafian and Tim Haines • Source: LSX World Congress

During a panel session at the recent LSX World Congress industry spectators discussed the state of biopharma investing and how companies can prepare now for the return of the public markets.

More from Business Strategy

More from In Vivo